Projects per year
Abstract
Current treatments for ischemic stroke focus on removing neurovascular-occluding clots but overlook the resulting neuroinflammation. Clinical trials targeting brain-infiltrating peripheral immune cells have failed to improved outcomes, leaving mechanisms of neuroinflammation poorly understood. Whilst many studies have examined the inflammatory cells and cytokine profile of the post-stroke brain at days and weeks following injury onset, we propose that interventions at these timepoints are too late to limit brain damage. In this study, we examined brain immune cell composition, cytokine levels, and neurological dysfunction at hyperacute (3 h) and acute (24 h) stages following a preclinical mouse model of ischemic stroke. Interestingly, we detected elevated inflammatory cytokines in brain tissue as early as 3 h, notably before infiltrating neutrophil and monocyte arrival at 24 h. Depletion of peripheral immune cells by antibodies or genetic alteration did not dampen neuroinflammation, nor improve sensorimotor function. Intravital imaging of Cx3cr1gfp/+ mice showed that microglia, the brain-resident immune cell, display rapidly altered morphology, and swiftly upregulated cytokine production hyperacutely post-stroke. Altogether, our study provides evidence that microglia are key drivers of early neuroinflammation and modulating their function at clinically-relevant timepoints will improve stroke recovery.
| Original language | English |
|---|---|
| Article number | 1193 |
| Number of pages | 15 |
| Journal | Communications Biology |
| Volume | 8 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 10 Aug 2025 |
-
Identify novel pharmacological approaches for limiting stroke - associated neuroinflammation and pneumonia
Wong, C. (Primary Chief Investigator (PCI))
1/01/24 → 31/12/27
Project: Research
-
TISN: Tackling ischaemic stroke with nanomedicine
Bourne, J. (Primary Chief Investigator (PCI)), Wong, C. (Chief Investigator (CI)), Veldhuis, N. (Chief Investigator (CI)), Whittaker, M. (Chief Investigator (CI)) & Lawlor, K. (Chief Investigator (CI))
1/01/23 → 31/03/24
Project: Research
-
Delivery of pH-responsive nanoparticles to reduce thrombo-inflammation and neural injury after ischaemic stroke
Wong, C. (Primary Chief Investigator (PCI)), Veldhuis, N. (Chief Investigator (CI)), Whittaker, M. (Chief Investigator (CI)) & Bourne, J. (Chief Investigator (CI))
1/01/23 → 31/12/24
Project: Research
Equipment
-
FlowCore (FLOW)
Fryga, A. (Manager)
Faculty of Medicine Nursing and Health Sciences Research PlatformsFacility/equipment: Facility
-
Monash Animal Research Platform (MARP)
Findlay, C. (Manager)
Faculty of Medicine Nursing and Health Sciences Research PlatformsFacility/equipment: Facility
-
Monash Biomedical Imaging (MBI)
Reid, K. (Manager), Brkljaca, R. (Manager), Hagemeyer, C. (Other) & Wright, D. (Other)
Office of the Vice-Provost (Research and Research Infrastructure)Facility/equipment: Facility
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver